Medline delivered 12% and 13% revenue and adjusted EBITDA growth, respectively, during the second quarter. Outlook for organic sales growth was raised by 50 basis points but fell 70 basis points for adjusted EBITDA margin. Shares fell 13% on Aug. 5.
Medline’s unrivaled scale in medical-surgical manufacturing and distribution enables the firm to enjoy long-term secular trends like an aging population and increased prevalence of chronic conditions.
Bears
Continued consolidation in the healthcare sector affords more buying power to large hospitals and GPOs and could lead to Medline conceding price and contracting margins.
Medline is the largest provider of medical-surgical products and supply chain solutions in the US. The company generates over 90% of its revenue domestically and serves some of the largest US health systems. Medline offers approximately 190,000 Medline-branded products across more than 250 product families—including front-line care, surgical solutions, and laboratory and diagnostics—as well as roughly 150,000 third-party products sourced from over 1,250 vendors. The company maintains prime vendor relationships with many customers, acting as the primary consolidated logistics partner for their medical-surgical needs. Medline has significant scale, supported by more than 30 manufacturing facilities and a fleet of over 2,000 owned delivery trucks. Medline went public in December 2025.